SUBSCRIBE
SUBSCRIBE

Rezolute, Inc.

NEWS
Woman With Pipette And Test Tubes
Drug Development
Clinical Catch-Up: Moderna COVID-19 Vaccine for Kids and Much More
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
March 25, 2022
 · 
10 min read
 · 
Mark Terry
Business
BioSpace Movers & Shakers, March 12
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
March 11, 2021
 · 
7 min read
 · 
Alex Keown
JOBS
IN THE PRESS
Drug Development
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
January 12, 2021
 · 
5 min read
Biotech Bay
Rezolute Announces Change of Transfer Agent
December 28, 2020
 · 
2 min read
Biotech Bay
FDA Clears Rezolute’s IND Application for RZ402RZ402 is an orally available plasma kallikrein inhibitor in development for the treatment of diabetic macular edema
December 3, 2020
 · 
4 min read
Biotech Bay
Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 19, 2020
 · 
2 min read
Deals
Rezolute Announces Uplisting to the Nasdaq Capital MarketTrading expected to begin November 9, 2020
November 5, 2020
 · 
3 min read
Biotech Bay
Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
October 9, 2020
 · 
3 min read
Business
Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
September 10, 2020
 · 
3 min read
Drug Development
Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
July 27, 2020
 · 
3 min read
Biotech Bay
Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
June 15, 2020
 · 
4 min read
Drug Development
Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
June 10, 2020
 · 
5 min read
Load More